Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for treating neuropathic pain associated with diabetic neuropathy ~~in a subject~~, the method comprising administering to a subject having neuropathic pain associated with diabetic neuropathy ~~in need thereof~~ a pharmaceutical composition comprising a therapeutically effective amount of a neublastin polypeptide, wherein the neublastin polypeptide exhibits neurotrophic activity and comprises an amino acid sequence that is at least 85% identical to amino acids 28-140 of SEQ ID NO:2, and wherein the pharmaceutical composition is administered to the subject via systemic delivery.

2-3. (Cancelled)

4. (Previously Presented) The method of claim 1, wherein the pharmaceutical composition is administered via intravenous delivery.

5. (Previously Presented) The method of claim 1, wherein the pharmaceutical composition is administered via subcutaneous delivery.

6-9. (Cancelled)

10. (Previously Presented) The method of claim 1, wherein the neublastin polypeptide is modified with a derivative moiety to have an extended residence time or increased concentration in body fluids.

11. (Previously Presented) The method of claim 10, wherein the derivative moiety is a polyethylene glycol moiety.

12. (Previously Presented) The method of claim 10, wherein the derivative moiety is selected from the group consisting of aliphatic esters, amides, N-acyl-derivatives, or O-acyl derivatives.

13-34. (Cancelled)

35. (Previously Presented) The method of claim 1, wherein said neuropathic pain is characterized by allodynia.

36. (Previously Presented) The method of claim 1, wherein said neuropathic pain is hyperalgesic pain.

37. (Previously Presented) The method of claim 36, wherein the hyperalgesic pain is thermal hyperalgesic pain.

38-56. (Cancelled)

57. (Previously Presented) The method of claim 35, wherein the allodynia is tactile allodynia.

58. (Previously Presented) The method of claim 35, wherein the pharmaceutical composition is administered via subcutaneous delivery.

59. (Previously Presented) The method of claim 35, wherein the pharmaceutical composition is administered via intravenous delivery.

60. (Previously Presented) The method of claim 36, wherein the pharmaceutical composition is administered via subcutaneous delivery.

61. (Previously Presented) The method of claim 36, wherein the pharmaceutical composition is administered via intravenous delivery.

62. (Previously Presented) The method of claim 37, wherein the pharmaceutical composition is administered via subcutaneous delivery.

63. (Previously Presented) The method of claim 37, wherein the pharmaceutical composition is administered via intravenous delivery.

64. (Previously Presented) The method of claim 57, wherein the pharmaceutical composition is administered via subcutaneous delivery.

65. (Previously Presented) The method of claim 57, wherein the pharmaceutical composition is administered via intravenous delivery.

66. (Cancelled)

67. (Previously Presented) The method of claim 1, wherein the neublastin polypeptide exhibits neurotrophic activity and comprises an amino acid sequence that is at least 90% identical to amino acids 28-140 of SEQ ID NO:2.

68. (Previously Presented) The method of claim 1, wherein the neublastin polypeptide exhibits neurotrophic activity and comprises an amino acid sequence that is at least 95% identical to amino acids 28-140 of SEQ ID NO:2.

69. (Currently Amended) The method of claim 1-66, wherein the neublastin polypeptide comprises amino acids 42-140 of SEQ ID NO:2.

70. (Currently Amended) The method of claim 1-66, wherein the neublastin polypeptide comprises amino acids 37-140 of SEQ ID NO:2.

71. (New) The method of claim 1, wherein the neublastin polypeptide comprises amino acids 28-140 of SEQ ID NO:2.

72. (New) The method of claim 4, wherein the neublastin polypeptide exhibits neurotrophic activity and comprises an amino acid sequence that is at least 90% identical to amino acids 28-140 of SEQ ID NO:2.

73. (New) The method of claim 4, wherein the neublastin polypeptide exhibits neurotrophic activity and comprises an amino acid sequence that is at least 95% identical to amino acids 28-140 of SEQ ID NO:2.

74. (New) The method of claim 4, wherein the neublastin polypeptide comprises amino acids 42-140 of SEQ ID NO:2.

75. (New) The method of claim 4, wherein the neublastin polypeptide comprises amino acids 37-140 of SEQ ID NO:2.

76. (New) The method of claim 4, wherein the neublastin polypeptide comprises amino acids 28-140 of SEQ ID NO:2.

77. (New) The method of claim 5, wherein the neublastin polypeptide exhibits neurotrophic activity and comprises an amino acid sequence that is at least 90% identical to amino acids 28-140 of SEQ ID NO:2.

78. (New) The method of claim 5, wherein the neublastin polypeptide exhibits neurotrophic activity and comprises an amino acid sequence that is at least 95% identical to amino acids 28-140 of SEQ ID NO:2.

79. (New) The method of claim 5, wherein the neublastin polypeptide comprises amino acids 42-140 of SEQ ID NO:2.

80. (New) The method of claim 5, wherein the neublastin polypeptide comprises amino acids 37-140 of SEQ ID NO:2.

81. (New) The method of claim 5, wherein the neublastin polypeptide comprises amino acids 28-140 of SEQ ID NO:2.